News

Here's what is coming soon to NeurologyLive®.

The neurologist and assistant professor at the University of Toronto discussed data presented at CTAD 2021 on RetiSpec, a retinal imaging tool that predicts brain amyloid status. [WATCH TIME: 3 minutes]

Speaking on his own presentation on economic burden in MS, Bruce Bebo, PhD, further shared his thoughts on areas of unmet need and the potential relationship of Epstein-Barr virus and MS.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Most of the 52 cognitive resilience proteins were found to be specific for cognitive decline and about 30% may provide resilience for both cognitive and noncognitive AD phenotypes.

A systematic literature review of randomized controlled trials in neuromyelitis optica spectrum disorder was performed, with 7 studies identified and 2 used in analyses.

Neurology News Network for the week ending March 12, 2022. [WATCH TIME: 4 minutes]

Investigators noted the long-term cost-effectiveness and safety of this approach, as it does not require the regular use of disease-modifying therapies.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 11, 2022.

The Muscular Dystrophy Association's annual meeting will take place in-person and virtually in Nashville, Tennessee, on March 13-16, with more than 950 in-person attendees and 130 presenters.

The assistant professor of neurology at the University of Pennsylvania discussed how 7T MRI features of newly developed MS lesions can predict the development of chronic active lesions. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Seema Khosla, MD, FCCP, FAASM. [LISTEN TIME: 29 minutes]

The study had a goal to provide a personalized treatment approach, including ASM dosage changes to prevent seizure worsening and optimizing the balance of outcomes for mothers and children.

Patients with chronic migraine on 60-mg once-daily and 30-mg twice-daily atogepant demonstrated reductions of 6.88 and 7.46 monthly migraine days, respectively, over a 12-week period.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]

Data from the 24-week, multicenter LibraTN trial are expected to be reported in the first half of 2024.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research offered her insight into improving the recognition of autoimmune encephalitis. [WATCH TIME: 2 minutes]

Bruce Bebo, PhD, outlined findings from a recent analysis presented at ACTRIMS Forum 2022, with investigators concluding costs associated with the disease have previously been underestimated.

The cohort study was conducted in Taiwan, with investigators also observing changes over time in the influence of sex, stroke type, and copayment exemption type of rehabilitation utilization.

In the EVOKE study (NCT02924129), the spinal cord stimulation system demonstrated superior pain relief compared to open-loop SCS at 12 months with no increase in pain medication.

The assistant professor of pediatric neurology at Washington University in St. Louis provided an overview of cerebral palsy and ways to reduce the risk of developing the condition. [WATCH TIME: 3 minutes]

Infection-related epilepsy etiology, experiencing multiple types of seizures, and cognitive impairment were independent influencing factors on perampanel use retention.

The William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, and Neurologist-in-Chief at Yale-New Haven Hospital spoke to the findings of a recent assessment of T cells in multiple sclerosis. [WATCH TIME: 4 minutes]

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

Data provide an update to the post-approval safety profile of cladribine tablets in patients with relapsing MS in reference to COVID-19 infections.

Investigators also found that this association was particularly pronounced among those living in nursing homes, as well as in Asian, Black, and Hispanic populations.

Leigh Charvet, PhD, professor of neurology, NYU Grossman School of Medicine, discussed the potential feasibility of at-home tDCS for patients with multiple sclerosis to boost cognitive training. [WATCH TIME: 2 minutes]

The neurodegeneration program lead at Genentech offered his perspective on the phase 3 SKYLINE trial and the historical data on gantenerumab ahead of this new clinical assessment.